ATAXIA UK — grant history

Registered charity 1102391 · filings on the Charity Commission register · its own accounts analysis · funder finder · deadlines · watch this funder · check a grantee list

Latest income
£1.8m
Grants listed (FY2025)
2
Listed grants total
£78k
Accounts grants total
£78k

listed grants reconcile with the accounts totalextracted from its FY2025 accounts

FY2023: 1 grant totalling £7k is listed but excluded from totals: unverified read (the amount is not printed in the accounts text).

FY2022: 1 grant totalling £61k is listed but excluded from totals: unverified read (the amount is not printed in the accounts text).

FY2021: 1 grant totalling £1.0m is listed but excluded from totals: unverified read (the amount is not printed in the accounts text).

Application guidance — from the funder’s own website

Summarised from www.ataxia.org.uk · www.ataxia.org.uk/support-services/grants/ · www.ataxia.org.uk/ataxia-research/for-researchers/research-funded-by-ataxia-uk/ on 17/08/2026. Always check the funder’s site before applying.

What changed: FY2024 → FY2025

Grantees that appear, disappear or move by 50%+ between the two most recent filings that have counted grants (unverified reads are left out, so a filing whose grants are all unverified is skipped). A grantee “dropped” may simply have received a multi-year grant earlier.

ChangeGranteeFY2024FY2025
newZ-Institut du Cerveau et de laMoelle épinière-ICM—£68k
newZ-Universidade de Lisboa—£10k
not listedDr Shiloh-Malawsky (University of North Carolina, US)£35k—
not listedDr Hubener-Schmid (University of Tubingen, Germany)£30k—
not listedProf Tremblay (Universite’ Laval, Canada)£8k—
not listedRealise Advocacy consultancy£6k—
not listedDr Abeti and Prof Giunti (UCL, UK)£5k—
not listedDr Anjoumani-Virmouni (Brunel University)£5k—
not listedProf Clayton (Great Ormond Street Institute of Child Health, UK)£5k—
not listedDr Hauser (DZNE, Germany)£4k—

Grants made, per its accounts filings

Download this grant history as CSV (open data, provenance and licence noted in the file).

RecipientYearAmountPurpose
Z-Institut du Cerveau et de laMoelle épinière-ICMFY2025£68kNovel biomarkers of oxidative stress in ataxia; Identification of disease-associated single nucleotide polymorphisms in ataxin-3; Evaluating ribosome collisions on CAG expansions proteostasis and translational; Consultancy support with respect to preparing for Health Technology Assessment; Effect of targeting sphingolipid- metabolising enzymes in iPSC-derived sensory neurons model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)
Z-Universidade de LisboaFY2025£10kRestoring NKX6-2 function by protein complementation: a proof-of-concept; Outcome measures in Mitochondrial disease and Spinocerebellar ataxias (R-PROMS)
Dr Shiloh-Malawsky (University of North Carolina, US)FY2024£35kExtension project “DRPLA Natural History and Biomarkers Study
Dr Hubener-Schmid (University of Tubingen, Germany)FY2024£30kDevelopment and Validation of SIMOA-based total and mutant Ataxin-2 Immunoassay for biomarker studies in SCA2 and SCA3
Prof Tremblay (Universite’ Laval, Canada)FY2024£8kNovel biomarkers of oxidative stress in Friedreich's ataxia
Realise Advocacy consultancyFY2024£6kPreparing for the health technology assessment process in FA
Dr Abeti and Prof Giunti (UCL, UK)FY2024£5kExploring novel iron-mediated mechanisms to prevent cellular death in Friedreich’s ataxia
Dr Anjoumani-Virmouni (Brunel University)FY2024£5kEffect of targeting sphingolipid-metabolising enzymes in iPSC derived sensory neurones obtained from FRDA patients
Prof Clayton (Great Ormond Street Institute of Child Health, UK)FY2024£5kNovel biomarkers of oxidative stress in Friedreich’s ataxia
Dr Hauser (DZNE, Germany)FY2024£4kIdentification of disease-associated single nucleotide polymorphisms in ataxin-3
Dr Matassa University of Naples, ItalyFY2024£3kEvaluating ribosome collisions on CAG expansions proteostasis and translational stress responses in Spinocerebellar Ataxia type 3
Prof Marios Hadjivassiliou (Sheffield Teaching Hospitals NHS Trust, UK)FY2023£38kImproving the diagnosis and management of gluten ataxia
Dr Karen Anthony (University of Northampton, UK)FY2023£31kEvaluation of RNA trans-splicing as a therapeutic strategy for spinocerebellar ataxia type 1
Dr Andreia Teixeira-Castro (University of Minho, Portugal)FY2023£30kTesting the multimodal anti-depressant vortioxetine as a therapeutic strategy to mitigate SCA3
Dr Roderick Maas (Radboud University Medical Center, The Netherlands)FY2023£30kLooking beyond the central nervous system in SCA3: nerve and muscle ultrasound as potential imaging markers to quantify and monitor peripheral nervous system degeneration.
Prof Paola Giunti (University College London, UK)FY2023£27kValidating the therapeutic effect, a CAG repeat-targeting antisense oligonucleotide, on mitochondrial physiology in cellular models of DRPLA
Prof Paola Giunti (University College London, UK)FY2023£25kDetermine mitochondrial metabolism in DRPLA: a possible novel therapeutic approach
UK ResearchersFY2023Unverified read£7kNine bursaries of £750 each to UK researchers to help them attend the International Congress for Ataxia Research
Dr Francesca Salvatori (University of Ferrara, Italy)FY2023£5kPersonalized gene editing approach for the treatment of Spinocerebellar Ataxia type 1 (SCA1)
Dr Pellerin (UCL)FY2023£2kDr David Pellerin travel grant award of £1500 to attend and present an oral presentation at the American Academy of Neurology 2023 Annual Meeting.
Gordon Research ConferenceFY2023£433$500 Sponsorship of CAG Triplet Repeat Disorders Gordon Research Conf and Seminar
University of North Carolina at Chapel Hill, USAFY2022£131kDRPLA Natural History and Biomarkers Study (DRPLA NHBS)
German Center for Neurodegenerative Diseases, Bonn, GermanyFY2022£80kAssessment of ataxia severity under real-life conditions with SARAhome: A multicenter study in spinocerebellar ataxia type 3 (SCA3)
Institut du Cerveau et de la Moelle épinière (ICM), FranceFY2022Unverified read£61kPreclinical development of an amelioration therapy for DentatorubroPallidoluysian Atrophy – Funding Extension
Instituto de Invesigacão e Inovacão em Saúde – i3S, PortugalFY2022£30kNanoSCA3: Development of brain-targeted nanobodies for application in spinocerebellar ataxia type 3 therapy
University College London, UKFY2022£5kBrain pathology in an AIFM1 mutation causing Cowchock syndrome
Imperial College London, UKFY2022£5kGeneration and characterization of a cardiomyocyte model for Friedreich’s ataxia to reveal the molecular mechanism of heart failure in patients
University of Brescia, ItalyFY2022£5kMotor and cognitive outcomes of non-invasive transcranial alternate current stimulation by entrainment of cerebellar oscillation
Newcastle University, UKFY2022£5kBalance and gait abnormalities in adult patients with mitochondrial disease and spinocerebellar ataxia type 6
Centro de Biología Molecular Severo Ochoa, Madrid, SpainFY2022£5kAnalysis of the mitochondrial dysfunction in FXN deficient neurones to generate a drug screening test
Strathclyde University, UKFY2022£3kA feasibility study of LSVT Artic to improve speech performance in people with progressive ataxia
Prof Paola Giunti (University College London, UK)FY2021Unverified read£1.0mComprehensive Biomarker Characterisation in Dentatorubral-Pallidoluysian Atrophy
Prof Henry Houlden (University College London, UK)FY2021£492kBiomarkers, Somatic Instability and creating a DRPLA cell line resource
Dr Heather Lau (NYU Grossman School of Medicine, USA)FY2021£126kThe DRPLA Natural History and Biomarker Study
Prof Louise Corben (Genetic Health Research & Murdoch Children's Research Institute, Australia)FY2021£71kInvestigating the use of the Ataxia Instrumented Measure – Spoon in measuring upper limb function in DRPLA
Dr Chelban and Prof Holden (UCL Institute of Neurology, London)FY2021£70kNKX6-2 Related Spastic Ataxia and Leukodystrophy: Natural history, biomarkers and the potential of gene transfer method
Prof Adam Vogel (Redenlab &The University of Melbourne, Australia)FY2021£51kRedenlab Scope of Work for the DRPLA Natural History Study (Speech and Dysphagia)
Dr Tremblay (Laval University, Canada)FY2021£35kDevelopment of a PRIME editing therapy for Ataxia-8 due to the c.121 A to T point mutation
Dr Filip Lim (University of Madrid, Spain)FY2021£30kGenerating new Friedreich’s Ataxia animal models for validating HSV-1 FXN gene therapy in Dorsal Root Ganglia Dr Lim
Dr D’Autreax (CNRS-CEA-Université Paris-Saclay, France)FY2021£26kDevelopment of a selective high throughput screening assay for the discovery of compounds replacing frataxin in FA
Dr Rufini, Fratagene Therapeutics (University of Rome)FY2021£20kEtravirine as a potential therapeutic for Friedreich ataxia
Prof LowitFY2021£6kA joint model of online Speech and language therapy intervention and peer support to enhance communication effectiveness and participation in people with progressive ataxia
Prof Horvath (Cambridge, UK)FY2021£5kPROSPAX: an integrated multimodal progression chart in spastic ataxias

About this data

This grant list is extracted by automated reading of the grant-maker’s own accounts PDFs as filed with the Charity Commission, and cross-checked against the accounts’ stated grant totals (listed sum 77768 vs reference 77768 (0.0% diff; ref=stated)). Recipients are linked to register entries only on an exact charity-number or unambiguous exact-name match. If you represent this funder or a recipient and want a correction, email [email protected].

Grants marked “Unverified read” were flagged by automated checks as possibly misread from the filed accounts. They stay in the list and the CSV (read_status column) but are left out of the totals, counts and recipient tallies this site computes.